VB10 NEO
Alternative Names: VB-10-NEO; VB10.NEOLatest Information Update: 28 Jan 2025
At a glance
- Originator Vaccibody
- Developer Nektar Therapeutics; Nykode Therapeutics
- Class Antineoplastics; Cancer vaccines; DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Squamous cell cancer; Urogenital cancer
- No development reported Solid tumours
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in Germany (IM, Injection)
- 28 Jan 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in Spain (IM, Injection)
- 04 Dec 2024 Pharmacodynamics data from a Preclinical trial in Cancer released by Nykode Therapeutics